ResMed (RMD) Stock Forecast & Price Target

$237.04

+0.98 (+0.42%)

(As of 10/9/2024 ET)

ResMed - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 13 Analyst Ratings

Sell
1

Hold
5

Buy
7

Based on 13 Wall Street analysts who have issued ratings for ResMed in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 1 has given a sell rating, 5 have given a hold rating, 6 have given a buy rating, and 1 has given a strong buy rating for RMD.

Consensus Price Target

$218.18
-7.96% Downside

According to the 13 analysts' twelve-month price targets for ResMed, the average price target is $218.18. The highest price target for RMD is $280.00, while the lowest price target for RMD is $169.00. The average price target represents a forecasted downside of -7.96% from the current price of $237.04.

Get the Latest News and Ratings for RMD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for ResMed and its competitors.

RMD Analyst Ratings Over Time

Type	Current Forecast 10/11/23 to 10/10/24	1 Month Ago 9/11/23 to 9/10/24	3 Months Ago 7/13/23 to 7/12/24	1 Year Ago 10/11/22 to 10/11/23
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	5 Buy rating(s)	6 Buy rating(s)	8 Buy rating(s)
Hold	5 Hold rating(s)	6 Hold rating(s)	5 Hold rating(s)	3 Hold rating(s)
Sell	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$218.18	$204.70	$202.80	$224.00
Forecasted Upside	-7.96% Downside	-19.03% Downside	-1.07% Downside	55.31% Upside
Consensus Rating	Moderate Buy	Hold	Moderate Buy	Moderate Buy

Bigger Than Nvidia? (Ad)

Bigger Than Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that's all they'll talk about.

Go here now for this breaking story.

RMD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

ResMed Stock vs. The Competition

Type	ResMed	Medical Companies	S&P 500
Consensus Rating Score	2.54	2.79	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	-7.96% Downside	10,995.04% Upside	7.34% Upside
News Sentiment Rating	Neutral News See Recent RMD News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/1/2024	Royal Bank of Canada 4 of 5 stars		Boost Target	Sector Perform ➝ Sector Perform	$206.00 ➝ $224.00	-6.55%
10/1/2024	Needham & Company LLC 2 of 5 stars	M. Matson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold
9/26/2024	Bank of America 4 of 5 stars		Boost Target	Buy ➝ Buy	$240.00 ➝ $270.00	+11.12%
9/24/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Rescott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
9/24/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$280.00	+13.74%
9/18/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Polark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Peer Perform ➝ Underperform	$180.00	-28.25%
Get the Latest News and Ratings for RMD and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.
8/2/2024	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$238.00 ➝ $251.00	+12.56%
6/25/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
6/24/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Chevrier Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
3/27/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$215.00	+9.88%
1/25/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$175.00 ➝ $180.00	-3.41%
1/9/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$160.00 ➝ $195.00	+7.32%
10/27/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Equal Weight ➝ Overweight	$180.00 ➝ $169.00	+21.82%
10/5/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$240.00 ➝ $165.00	+11.49%
1/31/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Kaczor Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 08:08 AM ET.

Should I Buy ResMed Stock? RMD Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, September 30, 2024. Please send any questions or comments about these ResMed pros and cons to contact@marketbeat.com.

ResMed
Bull Case

Here are some ways that investors could benefit from investing in ResMed Inc.:

ResMed Inc. has shown a consistent revenue growth of 6.9% compared to the same quarter last year, indicating a positive trend in the company's financial performance.
The company recently increased its dividend payout, signaling financial stability and potential for income generation for investors.
Institutional investors have been actively increasing their stakes in ResMed, with notable firms like Greenvale Capital LLP significantly growing their positions, reflecting confidence in the company's future prospects.
ResMed's stock price has been performing well, reaching $244.90 as of the latest trading day, showcasing strong market demand and investor interest in the company.
Wall Street analysts have provided positive ratings for ResMed, with an average target price of $204.70, indicating a favorable outlook for the company's stock.

ResMed
Bear Case

Investors should be bearish about investing in ResMed Inc. for these reasons:

Despite the positive revenue growth, the company's dividend payout ratio is relatively low at 32.57%, which may not be attractive for income-focused investors seeking higher dividend yields.
Some Wall Street analysts have issued neutral to underperform ratings on ResMed, suggesting potential risks or challenges that could impact the company's stock performance in the future.
Insiders at ResMed have been actively selling company shares, with significant amounts being divested over the last three months, which could raise concerns about insider sentiment or future company developments.
The stock's price-to-earnings ratio of 37.62 and price-to-earnings-growth ratio of 2.50 indicate that the stock may be trading at a premium valuation, potentially limiting short-term upside for investors.
ResMed's stock has reached a 52-week high of $255.18, suggesting that the stock may be approaching a peak in its price performance, which could lead to a period of consolidation or potential pullback.

RMD Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for ResMed is $218.18, with a high forecast of $280.00 and a low forecast of $169.00.
: 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last twelve months. There is currently 1 sell rating, 5 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RMD shares.
: According to analysts, ResMed's stock has a predicted downside of -7.96% based on their 12-month stock forecasts.
: Over the previous 90 days, ResMed's stock had 1 upgrade and 1 downgrade by analysts.
: ResMed has been rated by research analysts at Baird R W, Bank of America, KeyCorp, Needham & Company LLC, Robert W. Baird, Royal Bank of Canada, and Wolfe Research in the past 90 days.
: Analysts like ResMed less than other "medical" companies. The consensus rating score for ResMed is 2.54 while the average consensus rating score for "medical" companies is 2.79. Learn more on how RMD compares to other companies.